Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Shanghai Shyndec Pharmaceutical Co's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was ¥-112 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was ¥379 Mil.
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Shanghai Shyndec Pharmaceutical Co Selling, General, & Admin. Expense Related Terms
Shanghai Shyndec Pharmaceutical Co Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shyndec Pharmaceutical Co Selling, General, & Admin. Expense Chart
SHSE:600420 vs ZTS: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shyndec Pharmaceutical Co Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense falls into.
Shanghai Shyndec Pharmaceutical Co Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥379 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of ¥379 Mil mean?
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) has a Selling, General, & Admin. Expense of ¥379 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Shanghai Shyndec Pharmaceutical Co and its competitors.
Is Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense too high?
Shanghai Shyndec Pharmaceutical Co's current Selling, General, & Admin. Expense is ¥379 Mil. Overall, Shanghai Shyndec Pharmaceutical Co has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense compare to ZTS?
Shanghai Shyndec Pharmaceutical Co's Selling, General, & Admin. Expense of ¥379 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Shanghai Shyndec Pharmaceutical Co and its competitors. Shanghai Shyndec Pharmaceutical Co's current Selling, General, & Admin. Expense is ¥379 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shyndec Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co (SHSE:600420) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.79, compared to a current price of ¥8.29 — trading 23.2% below its estimated fair value. The current Selling, General, & Admin. Expense is ¥379 Mil. Shanghai Shyndec Pharmaceutical Co's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Shanghai Shyndec Pharmaceutical Co (SHSE:600420), the current Selling, General, & Admin. Expense is ¥379 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.29 is trading 23.2% below its estimated GF Value™ of ¥10.79.
GuruFocus considers Shanghai Shyndec Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600420:
Selling, General, & Admin. Expense: ¥379 Mil
GF Value™: ¥10.79 vs. price of ¥8.29 (23.2% below fair value)
No single metric tells the full story. See the SHSE:600420 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.
56GF Score
Get the complete analysis for SHSE:600420
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600420 has been successfully added to your 
